R&D Partner Content The Home of Accelerating Microbiome R&D 10th Annual Microbiome Movement returns with many new & exciting features including...
R&D Partner Content Accelerating Breakthroughs in Immunodermatology Drug Develop... Your Collaborative Forum to Shape the Future of Dermatology
R&D Partner Content Structure-Based Drug Design Summit Returns This June With tightening budgets and increasing pressure to de-risk R&D, pharma and biotech are shifting their focus toward smarter, more efficient drug design.
R&D Partner Content Returning for a 4th Year... GPCRs-Targeted Drug Discovery! Transforming the Discovery of Novel GPCR-Targeted Therapies
R&D Partner Content 2nd ESG in Life Sciences Summit Europe Mastering Life Science ESG Compliance & Strategic Impact in 2025
News Senju launches first-in-class dry eye disease drug in Japan Senju has launched a new drug for dry eye disease (DED) in Japan, Avarept, the first drug in the TRPV1 antagonist class to reach the market.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
